Hematologic Oncology

Rilzabrutinib has been approved by the FDA for persistent or chronic immune thrombocytopenia after an insufficient response to prior therapy.

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

The European Medicines Agency has granted orphan drug designation to OXC-101 for the treatment of acute myeloid leukemia.

The EMA granted orphan designation to ADX-2191 for the management of LBCL of immune-privileged sites, including primary vitreoretinal lymphoma.

Julie M. Vose, MD, MBA, details the rationale for evaluating epcoritamab for the treatment of patients with relapsed/refractory DLBCL with limited options.

Annamycin plus cytarabine produced a potential overall survival benefit in acute myeloid leukemia.

Samina Hirani, MD, discusses the evolving first-line treatment paradigm for patients with DLBCL and the unprecedented findings from the POLARIX trial.

UM171 cell therapy has earned European Commission approval for the treatment of patients with hematologic malignancies requiring HSCT.

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss the role of blinatumomab in acute lymphoblastic leukemia management.

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss first-line treatment options for acute lymphoblastic leukemia.

The top 5 OncLive videos of the week cover insights in polycythemia vera, multiple myeloma, colorectal cancer, LBCL, and mantle cell lymphoma.

Adjuvant atezolizumab boosts survival in bladder cancer, FDA clears companion diagnostic for nivolumab doublet in MSI-H/dMMR colorectal cancer, and more.

Pegtarazimod has received orphan drug designation from the European Medicines Agency for the management of graft-vs-host disease.

Glofitamab plus GemOx received approval in Canada for patients with relapsed or refractory DLBCL not otherwise specified who are not eligible for ASCT.

Naseema Gangat, MBBS, details updates, novel strategies, and factors that inform decision-making in clinical for patients with hematologic malignancies.

Three experts discuss the implications of the FDA's removal of REMS requirements for CAR T-cell therapy in hematologic malignancies in the following video.

The European approval of a zanubrutinb tablet formulation covers indications in CLL, Waldenström macroglobulinemia, MZL, and follicular lymphoma.

Upcoming oncology meetings in the second half of 2025 will present new data across tumor types and offering updates that may influence standards of care.

Supriya Gupta, MD, discusses updated efficacy data on liso-cel as second-line therapy for large B-cell lymphoma.

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, details the rationale for assessing a dual bispecific CAR T-cell therapy in relapsed/refractory LBCL.

Four expert hematologists discuss the FDA’s decision to remove REMS programs for CD19- and BCMA-directed CAR T-cell therapies in hematologic malignancies.

The top 5 OncLive videos of the week cover insights in MCL, prostate cancer, plexiform neurofibromas, breast cancer, and follicular lymphoma.

Vepdegestrant NDA under FDA review in ESR1-mutated breast cancer, Oncomine Dx Target Test gets greenlit as zongertinib companion diagnostic in NSCLC.

Naveen Pemmaraju, MD, discusses phase 2 data with pivekimab sunirine in frontline or relapsed/refractory blastic plasmacytoid dendritic cell neoplasms.

The development of SGR-2921 in relapsed/refractory AML and higher-risk MDS was discontinued followed by 2 patient deaths.